One company that could grow particularly dynamically due to its unique position is Vidac Pharma. Vidac's business model is based on a unique approach: reversing the Warburg effect. Cancer cells prefer to use glucose fermentation (Warburg effect) for energy, which leads to high glucose consumption and tumor growth. Vidac develops innovative active ingredients that detach the enzyme hexokinase-2 (HK2) from mitochondrial channels in order to normalize the degenerate metabolism of cancer cells. This blockade is intended to stop cell division and enable cell death to occur again. Vidac Pharma currently has two promising candidates – an ointment for skin cancer, which is in Phase 2 of clinical trials, and an active ingredient for solid tumors. The ointment for skin cancer in particular has shown impressive initial results: in an open-label study with patients with cutaneous T-cell lymphoma (CTCL stage I), the objective response rate was 56%. Complete remission was achieved in 22% of the subjects within eight weeks, and partial remission was observed in 34% of the study participants after eight to twelve weeks. All participants in the study remained progression-free for over four months, meaning that the cancer did not continue to grow.
News & Events